Source: Annual Congress 2013 –Diffuse pulmonary fibrosis



Rating:

Share or cite this content

Citations should be made in the following way:
X. He, D. Theegarten, J. Guzman, U. Costabel, F. Bonella (Essen, Bochum, Germany). Effect of pirfenidone (PFD) on cytokine/chemokine release from alveolar macrophages (AMs) in interstitial lung diseases (ILD): Preliminary results. Eur Respir J 2013; 42: Suppl. 57, 2334

Member's Comments

No comment yet.

Related content which might interest you: Effect of nintedanib on the release of angiogenic/angiostatic cytokines by alveolar macrophages (AMs) in interstitial lung diseases (ILD) Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Role of macrophage activation in type II alveolar cells transplantation for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung Year: 2013 The attenuating effect of erythropoietin (EPO) on the expression of myeloperoxidase (MPO) in bleomycin-induced pulmonary fibrosis in rats Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury Year: 2013 Thalidomide reduces IL-18, IL-8 and TNF-α release from alveolar macrophages in interstitial lung disease Source: Eur Respir J 2006 Oct 01;28(4):824-831 Year: 2006 Alveolar lymphocytes (AL) apoptosis in interstitial lung diseases (ILD). Increased AL apoptosis rate in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis Year: 2009 Pirfenidone suppresses proinflammatory and antiangiogenetic cytokine production by alveolar macrophages (AMs) in idiopathic non specific interstitial pneumonia (iNSIP) Source: International Congress 2014 – ILDs 2 Year: 2014 Effect of cigarette smoking on alveolar macrophages (AM) and lymphocytes (AL) apoptosis in selected interstitial lung diseases (ILD) Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease Year: 2008 High-dose N-acetylcysteine (NAC) in fibrotic interstitial lung diseases, a retrospective analysis Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP) Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 SMAD2 mRNA expression is upregulated in fibrosing interstitial lung diseases (ILDs) Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Effect of pirfenidone on IPF progression Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Pulmonary alveolar proteinosis: iPS derived macrophages as in-vitro disease model and potential source for novel gene and cell therapies Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Whole lung lavage efficacy in pulmonary alveolar proteinosis (PAP) is influenced by the infusion volume? Source: International Congress 2015 – IIPs: orphan Year: 2015 Enhanced apoptosis of alveolar lymphocytes (AL), but not macrophages (AM) in interstitial idiopathic pneumonias (IIPs). Special attention to idiopathic pulmonary fibrosis (IPF) results Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease Year: 2010 Increased apoptosis of alveolar lymphocytes (AL) in idiopathic pulmonary fibrosis (IPF). Potential mechanisms and practical considerations Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Inhibition of profibrotic signaling in fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) by histone deacetylase-inhibitors (HDACi) or the IPF drug pirfenidone Source: International Congress 2014 – ILDs 1 Year: 2014 Effect of nintedanib, pirfenidone, N-acetylcysteine and their combinations on cultured myofibroblast-type cells derived from patients with asbestosis and idiopathic pulmonary fibrosis Source: International Congress 2015 – Airway remodelling: recent developments Year: 2015 Inhaled GM-CSF in pulmonary alveolar proteinosis (PAP) patient refractory to plasmapheresis combined with multiple whole lung lavages (WLL) Source: International Congress 2016 – Orphan diseases I Year: 2016 Inhaled sargramostim and whole lung lavage (WLL) as therapy of autoimmune pulmonary alveolar proteinosis (aPAP) Source: International Congress 2016 – Orphan diseases I Year: 2016 Whole lung lavage therapy (WLL) of pulmonary alveolar proteinosis (PAP): A global survey of current practices and procedures Source: International Congress 2016 – Orphan diseases I Year: 2016